The first HPLC method was developed for the simultaneous determination of paracetamol (PC), ascorbic acid (AA), and pseudoephedrine HCl (PE) in their co-formulated tablets. Separation was achieved on a C18 column in 5 min using a mobile phase composed of methanol-0.05 M phosphate buffer (35:65, v/v) at pH 2.5 with UV detection at 220 nm. Linear calibration curves were constructed over concentration ranges of 1.0 -50.0, 3.0 -60.0 and 3.0 -80.0 μg mL -1 for PC, AA, and PE, respectively. The method was validated and applied for the simultaneous determination of these drugs in their tablets with average % recoveries of 101.17 ± 0.67, 98.34 ± 0.77, and 98.95 ± 1.11%, for PC, AA, and PE, respectively. The proposed method was also used to construct in vitro dissolution profiles of the co-formulated tablets containing the three drugs.
Introduction
The advantageous usage of combined therapy for the cure of common cold symptoms has been proven over mono-therapy. 1 Lately, fixed-dose combination tablets containing a unique nonsedating combination of paracetamol (PC), ascorbic acid (AA), and pseudoephedrine hydrochloride (PE) have been approved for the treatment of the common cold. PC (Fig. 1A , N-acetyl-paminophenol) is an analgesic and antipyretic with weak antiinflammatory activity, 2 and AA (Fig. 1B, 2 ,3-didehydro-L-threohexono-1,4-lactone) is a water-soluble vitamin possessing a useful effect under many conditions, e.g. the common cold, atherosclerosis, asthma, and Alzheimer's disease.
2 PE (Fig. 1C , (+)-(1S,2S)-2-methylamino-1-phenylpropan-1-ol hydrochloride) is a direct-and indirect-acting sympathomimetic. 2 The use of these three drugs in combination helps to relieve common cold symptoms, e.g. congestion, sinus pressure, fever, runny nose, headache, and sneezing. 1 PC, AA, and PE are official in the United States Pharmacopeia (USP) 3 and the British Pharmacopoeia (BP). 4 The USP 3 described a spectrophotometric assay for PC in pure form and HPLC methods for its formulations either alone or in combination with other drugs, while the BP 4 recommended a titrimetric assay for PC in pure form and a spectrophotometric assay for its tablets. On the other hand, the USP 3 described titrimetric methods for AA in pure form, oral solution, and tablets, and an HPLC method for injection. In the meantime, the BP 4 determined AA titrimetrically in pure from, injections, and tablets. For PE, the USP 3 used different HPLC methods for its pure form and different formulations either alone or with combined drugs, while the BP 4 used a titrimetric assay for PE pure form and HPLC method for its tablets and oral drops. As well, many methods were reported for the determination of binary mixtures containing two of the studied drugs either alone or with other drugs, such as spectrophotometry, 5, 6 HPLC, [7] [8] [9] electrokinetic chromatography, 10 and differential pulse voltammetry.
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To the best of our knowledge, no analytical method was reported for the simultaneous determination of a ternary mixture of PC, AA, and PE. Hence, our aims are: (i) to optimize and validate the first HPLC method for the simultaneous determination of these three drugs in their co-formulated tablets and (ii) to apply the developed method for in vitro dissolution testing of the co-formulated tablets. The in vitro dissolution behavior of a dosage form is correlated to its in vivo 
Notes
performance; 12 thus, a dissolution test is used to evaluate the batch-to-batch quality of a dosage form and to help in the production of new formulations. 13 Additionally, method validation according to ICH guidelines 14 and statistical evaluation of the data 15 will be conducted.
Experimental

Instruments
Chromatographic separation was performed using a Merck Hitachi HPLC system (Darmstadt, Germany) equipped with L-7100 chromatograph with a Rheodyne injector valve and 20 μL loop, L-7400 UV detector and D-7500 integrator. An NV P-901 digital pH-meter (Consort, Turnhout, Belgium) and a tablet dissolution tester from Abbota Corp., NJ, USA were used. A Promosil C18 column (4.6 × 250 mm, 5 μm particle size) from Agela Technologies Inc., NJ, USA and a Shim-pack CLC C8 column (4.6 × 250 mm, 5 μm particle size) from Shimadzu Corp., Kyoto, Japan were used.
Materials and reagents
All chemicals were of analytical reagent grade and solvents were of HPLC grade. Pure samples of PC and brimonidine tartrate (batch #RK12BRT007) were kindly provided by EIPICO Co. (10th of Ramadan City, Egypt). A pure AA sample (batch #1006815004) was kindly donated by Hebei Welcome Co., Shijiazhuang, China and a PE pure sample (batch #050727) was kindly given by Sigma Co. (Cairo, Egypt). The purity of the samples was checked by the official 3 and comparison 16 methods, and was found to be 100.20, 100.45, and 99.61% for PC, AA and PE, respectively. Sudo Flucet ® tablets (batch #MPO5911) labeled to contain 250 mg of PC + 50 mg of AA + 30 mg of PE/ tablet, product of Mash Premiere Co. (Badr city, Egypt) were purchased from the Egyptian market. Acetonitrile and methanol (HPLC grade) were procured from Sigma-Aldrich Co. (Munich, Germany). Sodium dihydrogen phosphate, disodium hydrogen phosphate dihydrate, and potassium dihydrogen phosphate were obtained from Adwic Co. (Cairo, Egypt). Orthophosphoric acid (85%, w/v) was obtained from Riedel-de Häen (Seelze, Germany).
Chromatographic conditions
Chromatographic separation was realized on a Promosil C18 column (4.6 × 250 mm, 5 μm particle size) from Agela Technologies Inc. using a mobile phase consisting of methanol-0.05 M sodium dihydrogen phosphate (35:65, v/v) mixture. The pH of the mixture was adjusted to 2.5 with 0.05 M orthophosphoric acid. The mobile phase was filtered with 0.45 μm Millipore membrane filter and degassed by sonication for 30 min, and then pumped at a flow rate of 1 mL min -1 . The UV detector was set at 220 nm. Brimonidine tartrate was used as an internal standard (IS).
Preparation of dissolution testing medium
Phosphate buffer (pH 5.8) was used as a dissolution test medium. It was prepared according to the USP guideline 3 by dissolving 1.19 g of disodium hydrogen phosphate dihydrate and 8.25 g of potassium dihydrogen phosphate in a suitable amount of water and diluting to 1000 mL with the same solvent.
Standard solutions
Standard solutions of PC, AA, PE and IS (1000.0 μg mL -1 ) were prepared in methanol. A standard AA solution was wrapped with aluminum foil so as to guard from light, since it is photosensitive. 17 All standard solutions were kept in a refrigerator (4 C) and were found to be stable for up to 3 days.
General procedures Constructions of calibration graphs.
Working solutions containing 1.0 -50.0, 3.0 -60.0 and 3.0 -80.0 μg mL -1 of PC, AA, and PE, respectively, were prepared by dilution of standard solutions and an aliquot of the IS (giving a concentration of 30.0 μg mL -1 ) with the mobile phase. Twenty μL were injected and analyzed under the optimal conditions. Experiments were repeated three times for each concentration. Calibration graphs were constructed by plotting the average peak-area ratios (drug/ IS) versus the drug concentration in μg mL -1 , and the corresponding regression equations were derived.
Analysis of laboratory-prepared mixtures of the studied drugs.
Laboratory-prepared mixtures of PC, AA, and PE (25:5:3, respectively) together with the IS, were prepared in the mobile phase. Twenty microliters were injected and analyzed under the optimum chromatographic conditions. The % recoveries of each drug were determined from the corresponding regression equation. Analysis of tablets by standard addition technique. Ten tablets were accurately weighed, pulverized, and homogenized. An amount of the powder corresponding to 250 + 50 + 30 mg of PC, AA, and PE stated active principles, respectively, was weighed and transferred to a 100 mL volumetric flask. The volume was completed with methanol, followed by sonication for 30 min, and then filtration. Aliquots of this solution together with the IS were transferred to a series of 10 mL volumetric flasks and spiked with portions of PC, AA, and PE standard solutions to obtain final concentrations within the specified ranges. The mobile phase was added to adjust the final volume. The solutions were mixed well, and triplicate 20 μL injections were made for each sample. Standard-addition plots were generated by plotting the average peak-area ratios (drug/IS) versus the drug concentrations (μg mL -1 ). The regression lines were extrapolated to the point on the x-axis at which y = 0. The absolute value of the x-intercept corresponds to the drug concentration. Dissolution testing. Dissolution testing was performed using a paddle-type apparatus at 50 rpm. The dissolution medium (900 mL of phosphate buffer of pH 5.8) was deaerated by sonication for 30 min and kept at 37 ± 0.5 C. The tablet was introduced into the dissolution apparatus and the vessel was covered so as to minimize evaporation. Then, 5 mL samples were withdrawn at 5 min time intervals up to 45 min, and then at 10 min time intervals until 90 min. The withdrawn solutions were replaced with a fresh dissolution medium (37 ± 0.5 C). The samples were immediately filtered. Appropriate aliquots were transferred to 10 mL volumetric flasks together with the IS and completed to the final volume with the mobile phase. Twenty μL were injected in triplicate and chromatographed. The percentages drugs released were calculated and plotted versus time (min) so as to construct dissolution profiles of the three drugs.
Results and Discussion
Optimization of chromatographic conditions
Different chromatographic conditions were optimized to achieve the best separation within a short analysis time with the highest sensitivity. The UV detection was set at 220 nm, while allowing for the determination of the three drugs with a proper sensitivity, where PC and AA have absorption maxima at 244 nm and PE at 206 nm. C18 and C8 columns were tried as stationary phases; and the C18 column was the most suitable. The type of organic modifier (methanol or acetonitrile) and its ratio (from 25 to 37%, v/v), the molar strength of phosphate buffer (from 0.005 to 0.1 M), and the pH of the mobile phase (from 2.3 to 4.5) were explored. The selection of the optimum conditions was based on obtaining good resolution with the highest theoretical plate count and the best peak symmetry within a short analysis time. After these studies, a mobile phase consisting of a methanol-0.05 M phosphate buffer (35:65, v/v) mixture of pH 2.5 was selected as the optimum. Brimonidine tartrate was used as IS, giving a well-separated peak at a reasonable retention time (tR). A summary of the method optimization is presented in Table S1 (Supporting Information).
Under the optimum chromatographic conditions, good resolutions of AA (tR = 2.4 min), PC (tR = 3.8 min), PE (tR = 4.7 min) and IS (tR = 3.0 min) were achieved. The resolution factors were 3.0, 2.9, and 3.6 for AA/IS, IS/PC, and PC/PE pairs, respectively. Furthermore, the theoretical plate counts for AA, PC, and PE were 2298, 3722, and 5711, respectively. Good peak symmetry was evidenced by reasonable values of the tailing factors, which did not exceed 1.5 for all of the chromatographic peaks.
Method validation
The proposed method was validated according to the ICH Q2 (R1) guidelines. 14 A linear correlation was established between the peak-area ratios (drug/IS) and the drug concentrations over the ranges cited in Table 1 . The results of a statistical analysis of the data 15 indicated good linearity of the developed method ( Table 1 ). The limit of quantitation (LOQ) and the limit of detection (LOD) were also calculated according to ICH Q2 (R1), 14 while adopting the approach of the standard deviation of the intercept of the regression line and the slope (Table 1) .
To test the accuracy, the method was applied for the determination of 3 drugs in pure form. Statistical evaluations of the results obtained by the proposed method using the Student's t-test and the variance ratio F-test 15 revealed no significant Table 3 Precision data for the determination of the studied drugs in the pure form by the proposed method differences between its performance and that of the official methods for PC and PE 3 and a comparison HPLC method for AA 16 concerning the accuracy and the precision, respectively ( Table 2 ).
An evaluation of the intra-day precision was achieved by analyzing the studied drugs in pure form at 3 concentration levels for 3 consecutive times. Assessing the inter-day precision was also done through analyses of the studied drugs at 3 concentration levels on 3 consecutive days. The small values of SD and %RSD indicate the high precision of the proposed method ( Table 3) .
The method robustness was also estimated. A slight deliberate deviation in the mobile phase pH (2.5 ± 0.2), % of methanol (35 ± 2%, v/v), and concentration of phosphate buffer (0.05 ± 0.005 M) had no influence on the separation and resolution of the studied drugs.
The selectivity of the proposed method was also evaluated by the analyses of laboratory-prepared mixtures of PC, AA, and PE in the ratio of 25:5:3, respectively, without any overlapping (Fig. S1, Supporting Information) . The satisfactory recovered concentrations and the small values of %RSD and %Error (Table S2 , Supporting Information) showed the ability of the proposed method to determine each drug in this ternary mixture without any interference from the co-existing drugs. The proposed method allowed for the determinations of PC, AA, and PE in their co-formulated tablets without interference from common additives, evidencing its specificity.
Applications
Assay of co-formulated tablets. The developed method was applied to the analysis of tablets containing a ternary mixture of the three drugs. Since there is no analytical method that has been published for simultaneous analyses of this ternary mixture, the standard-addition technique was applied to determine the accuracy of the proposed method, as recommended by ICH Q2 (R1).
14 The obtained results were accurate and in good agreement with the label claim (Table 4 ). Figure 2 illustrates a chromatogram for the three drugs in tablets. Being the first HPLC method for the determination of PC, AA, and PE simultaneously, the proposed method is well-suited for qualitycontrol laboratories. In vitro dissolution testing. Due to its robustness and selectivity together with its rapidness (total analysis time of about 5 min) which allowed for the analysis of a large number of samples generated from dissolution experiments, the proposed method is suitable for dissolution testing of a tablet formulation containing a ternary mixture of PC, AA, and PE.
The conditions described by the USP 3 for the dissolution testing of tablets containing PC/PE binary mixture was implemented using phosphate buffer (pH 5.8) as a dissolution medium. Similar conditions were used by the USP 3 for dissolution testing of AA tablets, except for the use of water as a dissolution medium. The use of water as a dissolution medium is not generally preferable, since the quality of water can vary depending on the source of water; also the pH of water may vary from day to day, and can also change during the experiment, depending on the active substances and the excipients. 3 Hence, it was concluded that using phosphate buffer would be more suitable for the three drugs.
The dissolution profile for the immediate release tablets containing the three drugs showed a gradual increase reaching 92, 90 and 96% at about 35, 45, and 40 min for PC, AA, and PE, respectively (Fig. 3) . The obtained results agreed well with the acceptance criteria stated by the USP 3 for immediate release products, expressed as percentage of the labeled content (Q) (Q = 85 -100% in 30 -45 min). 3 The obtained results confirmed the suitability of the proposed method for the dissolution testing of co-formulated tablets containing PC, AA, and PE.
Conclusions
A new HPLC method was developed and validated for simultaneous determinations of PC, AA, and PE in their co-formulated tablets. The developed method was found to be simple, accurate, robust, precise, and rapid. Hence, an in vitro dissolution test was designed to assess the performance of commercially available tablets containing the three drugs. All of the obtained results were within the USP acceptance criteria. Table S1 gives results of the method optimization study and Table S2 represents the results for the determination of the 3 studied drugs in laboratories prepared mixtures. Figure S1 illustrates the good separation of the studied drugs in laboratoryprepared mixture. This material is available free of charge on the Web at http://www.jsac.or.jp/analsci/.
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